Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Top Cited Papers
Open Access
- 1 July 2011
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 121 (7), 2768-2780
- https://doi.org/10.1172/jci45600
Abstract
Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently under evaluation in oncology clinical trials are largely not tumor selective. To be clinically successful, the next generation of nanoparticle agents should be tumor selective, nontoxic, and exhibit favorable targeting and clearance profiles. Developing probes meeting these criteria is challenging, requiring comprehensive in vivo evaluations. Here, we describe our full characterization of an approximately 7-nm diameter multimodal silica nanoparticle, exhibiting what we believe to be a unique combination of structural, optical, and biological properties. This ultrasmall cancer-selective silica particle was recently approved for a first-in-human clinical trial. Optimized for efficient renal clearance, it concurrently achieved specific tumor targeting. Dye-encapsulating particles, surface functionalized with cyclic arginine–glycine–aspartic acid peptide ligands and radioiodine, exhibited high-affinity/avidity binding, favorable tumor-to-blood residence time ratios, and enhanced tumor-selective accumulation in αvβ3 integrin–expressing melanoma xenografts in mice. Further, the sensitive, real-time detection and imaging of lymphatic drainage patterns, particle clearance rates, nodal metastases, and differential tumor burden in a large-animal model of melanoma highlighted the distinct potential advantage of this multimodal platform for staging metastatic disease in the clinical setting.This publication has 53 references indexed in Scilit:
- Hybrid PET-optical imaging using targeted probesProceedings of the National Academy of Sciences of the United States of America, 2010
- In Vivo Biodistribution and Clearance Studies Using Multimodal Organically Modified Silica NanoparticlesACS Nano, 2010
- Design considerations for tumour-targeted nanoparticlesNature Nanotechnology, 2009
- Molecular imaging and therapy of cancer with radiolabeled nanoparticlesNano Today, 2009
- Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living SubjectsCancer Research, 2009
- Particle Size, Surface Coating, and PEGylation Influence the Biodistribution of Quantum Dots in Living MiceSmall, 2009
- Imaging in the era of molecular oncologyNature, 2008
- Multimodal Nanoprobes for Radionuclide and Five-Color Near-Infrared Optical Lymphatic ImagingACS Nano, 2007
- Renal clearance of quantum dotsNature Biotechnology, 2007
- Image-Guided Oncologic Surgery Using Invisible Light: Completed Pre-Clinical Development for Sentinel Lymph Node MappingAnnals of Surgical Oncology, 2006